Grail (GRAL) is making its Galleri multicancer early detection test directly available to physicians in the US through its collaboration with Quest Diagnostics (DGX), the companies said Wednesday.
The companies said the test can now be ordered from Grail through Quest's connectivity system, helping streamline the process of ordering for physicians.
The integration of Grail's test into Quest's connectivity system will also increase availability by making the test accessible to patients at any Quest patient access point, the companies said.
Financial details of the collaboration weren't provided.
Price: 33.01, Change: -0.14, Percent Change: -0.42
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。